ArticleScientific reports2026
PRRs-related genes and immune landscape in heart failure and COPD.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are major health issues causing high hospitalization and mortality rates. Pattern recognition receptor-related differentially expressed genes (PRDEGs) play a crucial role in disease progression, as their altered expression patterns are closely linked to immune responses, inflammatory processes, and tissue remodeling. Understanding PRDEGs is vital for effective diagnostics and therapies. This study incorporated four GEO datasets (GSE57338, GSE16499, GSE76925, and GSE57148). Among them, GSE57338 and GSE76925 served as the primary analysis sets for HF and COPD, respectively, where differential expression, functional enrichment, and immune infiltration analyses were performed. GSE16499 and GSE57148 were used as independent validation sets to confirm the key findings. Seven PRDEGs, including PTX3, UCHL1, IL1R1, PLA2G2A, CXCL12, SPP1, and CD24, which exhibited significant expression differences in both HF and COPD. Enrichment analysis revealed that these genes were primarily associated primarily with biological processes such as the regulation of cellular extravasation and leukocyte migration, as well as the NF-kappa B signaling pathway. Immune infiltration analysis indicated significant differences in the abundances of various immune cells in HF and COPD samples. This study identified 7 PRDEGs as biomarkers, emphasizing the need to explore key genes and pathways in HF and COPD, along with 9 immune cell types and 2 signaling pathways, suggesting immune modulation's role in treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.